DERMOLIN ® Fluocinolone

DERMOLIN ® is a drug based on Fluocinolone acetonide

THERAPEUTIC GROUP: Non-associated corticosteroids, dermatological preparations

Indications DERMOLIN ® Fluocinolone

DERMOLIN ® is indicated in the treatment of all those local inflammatory pathologies sensitive to treatment with corticosteroids.
Dermatitis, eczema, lupeic lesions, neuroderms, psoriasis, alopecia areata, contact dermatitis, insect bites, burns, traumatic ulcers and erythema are just some of the potential therapeutic indications for Fluocinolone acetonide.

Mechanism of action DERMOLIN ® Fluocinolone

DERMOLIN ® is a medicinal specialty based on Fluocinolone acetonide, a steroid derived from hydrocortinsone and fluorinated in order to optimize its therapeutic efficacy.
Similarly to other corticosteroid drugs, Fluocinolone also owes its anti-inflammatory, vasoconstrictive and anti-allergic activity to the ability to easily permeate cell membranes, inducing the expression of Lipocortin, a protein capable of inhibiting the Phosdolipase A2 enzyme, blocking the cascade upstream of inflammatory events leading to the formation of mediators of inflammation.
All this translates into the optimal control of the complained symptoms and the gradual improvement of the patient's clinical conditions.
All this is also facilitated by the good pharmacokinetic properties of Fluocinolone acetonide applied topically, which by limiting the systemic absorption of the active principle guarantee a significant reduction of potential side effects.

Studies carried out and clinical efficacy

Am J Dermatopathol. 2009 Dec; 31: 794-8. doi: 10.1097 / DAD.0b013e3181a9070d.

A histological examination for skin atrophy after 6 months of treatment withfluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream.

Bhawan J, Grimes P, Pandya AG, Keady M, Byers HR, Guevara IL, Colón LE, Johnson LA, Gottschalk R.

Work that tries to characterize the risk of skin atrophy following the topical application of Fluocinolone. Fortunately all the data seem to agree on the low risk of this effect even after prolonged treatments up to 24 weeks.

J Endod. 2011 Feb; 37: 181-4. doi: 10.1016 / j.joen.2010.10.013.

Effect of fluocinolone acetonide on human dental pulp cells: cytotoxicity, proliferation, and extracellular matrix formation.

Muincharern W, Louwakul P, Pavasant P, Lertchirakarn V.

Dental study that demonstrates how low concentrations of FLuocinolone can have a particular clinical efficacy in promoting the healing of the inflamed dental pulp.

Retina. 2012 Mar; 32: 537-42. doi: 10.1097 / IAE.0b013e31822058bb.

Treatment of intractable posterior uveitis in pediatric patients with thefluocinolone acetonide intravitreal implant (Retisert).

Patel CC, Mandava N, Oliver SC, Braverman R, Quiroz-Mercado H, Olson JL.

Very recent study that demonstrates how Fluocinolone acetonide-based implants can be effective in controlling posterior inflammation in small patients suffering from cataracts and glaucoma.

Method of use and dosage

0.25% Fluocinolone acetonide ointment.
In most cases, the application of the appropriate quantity of ointment directly on the region affected by the inflammatory process 2-3 times a day guarantees a prompt remission of the complained symptoms.
In other cases, again according to medical indications, the treatment could be enhanced by the use of the occlusive bandage, taking care to replace the dressing every 12 hours, until healing.

Warnings DERMOLIN ® Fluocinolone

Treatment with DERMOLIN ® should be preceded by a careful medical examination aimed at clarifying the origin of the complained lesions and any prescriptive appropriateness.
The patient should also:

  • avoid applying the medicine to eyes and mucous membranes;
  • avoid using the drug for particularly long periods of time;
  • avoid the application of the drug on particularly wide skin regions;
  • clean your hands after each application;
  • contact your doctor immediately following the appearance of side effects.


The use of DERMOLIN ® during pregnancy and in the subsequent period of breastfeeding is generally contraindicated.
Any use, justified by a cost-benefit ratio decidedly in favor of the benefits, should necessarily be supervised by specialist medical personnel.


There are currently no known drug interactions worthy of clinical note.

Contraindications DERMOLIN ® Fluocinolone

The use of DERMOLIN ® is contraindicated in patients hypersensitive to the active substance or to one of its excipients.

Undesirable Effects - Side Effects

The use of DERMOLIN ® could determine the appearance of local side effects such as edema, burning, irritation, hair loss, hypertrichosis, skin atrophy, dry skin and dermatitis.
Fortunately, all potential systemic side effects are rarer.


DERMOLIN ® is a drug subject to mandatory medical prescription.

The information on DERMOLIN ® Fluocinolone published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.

none:  pharmacology food intolerance underwater